Sustained Release of Heparin From Plla Micropartricles for Tissue Engineering Applications Publisher



Rajabi M¹ ; Shabani I¹ ; Ahmadi Tafti SH² ; Shabani A³ Show Affiliations
Source: Polymer Testing Published:2024

Abstract

Heparin holds promise for cardiac tissue engineering, but challenges such as hematoma or bleeding and accumulation in tissue caused by excessive release, and short half-life persist. The present study aimed to introduce a reliable mechanism for the prolonged heparin release from a biocompatible polymer carrier. The designed system must ensure that heparin retains its bioactivity over time while preventing premature release. Heparin was encapsulated within poly (L-lactic acid) microparticles using the double emulsion method, with polyvinyl alcohol employed as the stabilizer. The encapsulation efficiency of heparin in the microparticles was calculated as 25.56 %. The functionality of the design was evaluated using Attenuated Total Reflection Fourier Transform Infrared Spectroscopy, Scanning Electron Microscopy, and Energy Dispersive X-ray Spectroscopy. Drug release and microparticle degradation studies were conducted alongside cell viability tests. The particle sizes ranged from 5 to 10 ± 2.53 μm, with evidence suggesting that heparin promotes the smaller particle formation. The system demonstrated a consistent drug release profile over six weeks with a release rate of 54 % by week two and 97.65 % by week six. The degradation of heparin-loaded microparticles reached less than 50 % by week six, and the loading of heparin did not significantly affect the degradation behavior of the PLLA microparticles in PBS. Furthermore, heparin concentrations between 200 and 400 μg/ml enhanced the viability of Placenta-derived Mesenchymal Stem Cells and H9c2. These findings suggest that the system could be considered as an effective vehicle for sustained heparin delivery across a spectrum of biological applications, particularly in cardiac tissue engineering. © 2024 The Authors